BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 18841151)

  • 1. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib.
    Billemont B; Medioni J; Taillade L; Helley D; Meric JB; Rixe O; Oudard S
    Br J Cancer; 2008 Nov; 99(9):1380-2. PubMed ID: 18841151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma.
    Oh JJ; Hong SK; Joo YM; Lee BK; Min SH; Lee S; Byun SS; Lee SE
    Jpn J Clin Oncol; 2012 Apr; 42(4):314-7. PubMed ID: 22323554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term response with sunitinib for metastatic renal cell carcinoma.
    Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
    Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
    J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.
    Noé G; Bellesoeur A; Thomas-Schoemann A; Rangarajan S; Naji F; Puszkiel A; Huillard O; Saidu N; Golmard L; Alexandre J; Goldwasser F; Blanchet B; Vidal M
    Oncotarget; 2016 Oct; 7(41):67507-67520. PubMed ID: 27589830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.
    Narayanan S; Callis-Duffin K; Batten J; Agarwal N
    Am J Med Sci; 2010 Jun; 339(6):580-1. PubMed ID: 20421784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis.
    Medioni J; Choueiri TK; Zinzindohoué F; Cho D; Fournier L; Oudard S
    J Urol; 2009 Jun; 181(6):2470-5; discussion 2475. PubMed ID: 19371877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
    Grossmann M; Premaratne E; Desai J; Davis ID
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
    Vroling L; van der Veldt AA; de Haas RR; Haanen JB; Schuurhuis GJ; Kuik DJ; van Cruijsen H; Verheul HM; van den Eertwegh AJ; Hoekman K; Boven E; van Hinsbergh VW; Broxterman HJ
    Angiogenesis; 2009; 12(1):69-79. PubMed ID: 19212818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The changes in complete blood count in patients treated with sunitinib malate for metastatic clear cell renal cell carcinoma].
    Kucharz J; Michałowska-Kaczmarczyk A; Streb J; Kuzniewski M; Herman RM; Krzemieniecki K
    Przegl Lek; 2013; 70(9):712-4. PubMed ID: 24455830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
    Neill MG; Wei AC; Jewett MA
    Urology; 2007 Jul; 70(1):178.e9-11. PubMed ID: 17656238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
    Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
    Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [News on ASCO 2007. Sunitinib in the treatment of metastatic renal carcinoma and gastrointestinal stromal tumors].
    Mansueto G; Longo F
    Tumori; 2007; 93(5):Suppl 1-16. PubMed ID: 18038894
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Shaheen PE; Rini BI; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
    Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
    Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array.
    Perez-Gracia JL; Prior C; Guillén-Grima F; Segura V; Gonzalez A; Panizo A; Melero I; Grande-Pulido E; Gurpide A; Gil-Bazo I; Calvo A
    Br J Cancer; 2009 Dec; 101(11):1876-83. PubMed ID: 19904265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.